Oncotelic Therapeutics Inc (OTLC OTCQB) stock market data APIs
$0.1009
0(0%)
as of October 17, 2025
Try our APIs with
free plan!
Oncotelic Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications. It develops antisense and small molecule injectable drugs for the treatment of cancer. The company is also developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, it develops CA4P for the treatment of advanced metastatic melanoma; AL-101, an intranasal drug and delivery system for intra-nasal apomorphine for the treatment of parkinson's disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies, as well as nanoparticle products for the treatments of various cancers. The company is headquartered in Agoura Hills, California.
Prev. Close
0.1009
Open
0.1009
High
0.1009
Low
0.0906
52 wk Range
0.02-0.1
Market Cap
43 493 K
Shares Outstanding
435 M
EPS
0.0006
Beta
-0.692
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oncotelic Therapeutics Inc data using free add-ons & libraries
Get Oncotelic Therapeutics Inc Fundamental Data
Oncotelic Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -552 028
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-29
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oncotelic Therapeutics Inc News
New
Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium
SYDNEY, Australia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – Sapu Nano today announced the presentation of its poster, “Sapu-003: Novel Intravenous Deciparticle™ Everolimus Entering Phase 1 ...
Sapu Nano 的 Sapu003 进入人体临床试验 —— 革新给药方式，实现 Everolimus 全生物利用度，造福乳腺癌患者
Sapu003 旨在克服 Afinitor®（FDA 批准的口服 Everolimus）的局限性，通过静脉注射实现 Everolimus 的全效给药 悉尼澳大利亚, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Decipart...
Sapu Nano 展開編號為 Sapu003 的臨床試驗 —— 以完全生體可用率革新 Everolimus(依維莫司) 給藥方式，為乳癌治療開啟新篇章
Sapu003 旨在突破 FDA 核准口服藥物 Everolimus（Afinitor®，癌伏妥）的療效瓶頸，以 靜脈注射方式提供完整且高效率的 Everolimus 輸送。 澳洲雪梨, Sept. 30, 202...
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, Delivering Full Strength of Everolimus via Intravenous Injection AUSTRALIA, Sydney, Sept. 24, 2025 (GLOBE NEWSW...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
